National Cancer Institute Home at the National Institutes of Health | www.cancer.gov

Publication Abstract

Authors: Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD

Title: Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.

Journal: Cancer Invest 29(9):573-84

Date: 2011 Nov

Abstract: We used Surveillance, Epidemiology, and End Results-Medicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HR] 0.54; 95% Confidence Interval [CI] 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.

Last Modified: 03 Sep 2013